1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokineti...
1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundPRJ1–3024 is a small molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor designed to enhance T-cell function and anti-tumor responses. HPK1 is an immunosuppressive regulatory kinase with a restricted expression profile in hematopoietic compartment.1 2 HPK1 kinase activity suppresses immune functions of a wide range of cells includ...
Alternative Titles
Full title
1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0031d9b13ecc4dc5b45d38d817221921
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0031d9b13ecc4dc5b45d38d817221921
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.1073
